Dear MAPS Members and Friends,
I’m reminded of something my mother often says: “If you don’t know anything, you don’t have to do anything.” Well, we certainly have a lot to do these days.
Each new study and each new experimental session gives us another opportunity to refine our methods, improve our results, and move MDMA-assisted psychotherapy ever closer to approval as a legal treatment for posttraumatic stress disorder (PTSD).Make a Contribution
Last week, our MDMA-assisted psychotherapy for PTSD research program reached a major milestone when the long-term follow-up results from our U.S. flagship study were submitted for publication in a scientific journal.
The results suggest that MDMA-assisted psychotherapy isn’t just a short-term treatment, but may be a lasting cure for some people suffering from chronic, treatment-resistant PTSD.
Here are just a few highlights from this month’s newsletter:
- Our ongoing U.S. study of MDMA-assisted psychotherapy for veterans with PTSD expands from 16 to 24 subjects, enabling researchers to make stronger claims about treatment effectiveness.
- The protocol for our upcoming Australian study of MDMA-assisted psychotherapy for PTSD is completed and submitted to an Australian Ethics Committee.
- "The Principles of Psychedelic Therapy" workshop, led by MDMA-assisted psychotherapy researchers Dr. Michael Mithoefer and Annie Mithoefer, B.S.N., at Cartographie Psychedelica is now available online.
- British Columbia’s chief medical official, Dr. Perry Kendall, recognizes the promise of MDMA-assisted psychotherapy on CBC Radio One.
- MAPS’ research makes the front page of the Santa Cruz Weekly.
With your support, MAPS is healing people and transforming culture by developing psychedelics and marijuana into prescription medicines.
MAPS Director of Communications